Neopharmed Gentili to acquire the European business of ORLADEYO from BioCryst Pharmaceuticals for $264m.

Neopharmed Gentili, an Italian pharmaceutical company, agreed to acquire the European business of ORLADEYO from BioCryst Pharmaceuticals, a biotech firm focused on oral therapies for rare diseases, for $264m. “This transaction marks the beginning of a new path for Neopharmed Gentili, projecting the company onto the international stage and rare disease field, leveraging its deep Italian roots and welcoming a successful and experienced European team. This acquisition confirms and further strengthens our long-term growth trajectory, consolidating our position as a leading European specialty pharmaceutical company,” Alessandro Del Bono, Neopharmed President and CEO.